Copyright thehindubusinessline
Piramal Pharma posted a loss of ₹99 crore for the second quarter ended September 30, 2025, impacted by inventory destocking on a commercial, on-patent product in the contract development and manufacturing organisation (CDMO) segment. The drugmaker’s revenue from operations for the quarter under review was down 9 per cent, at ₹2,044 crore. Nandini Piramal, Chairperson, Piramal Pharma said, “Year-on-Year (y-o-y) growth in the CDMO Business was primarily impacted by inventory destocking in one large on-patent commercial product. Inconsistent recovery in US biopharma funding along with uncertainties on global trade policies led to adverse impact on order inflows and customer decision making during H1FY26. However, in September and October 2025, we have seen a significant pick up in biopharma funding, which if sustains, should lend impetus to increased RFPs and orders going forward.” Further, she said, they were “seeing strong customer interest for onshore offerings which bodes well for the investments we have made in our overseas sites. In our CHG business we further strengthened our leadership position in the US Sevoflurane market, while simultaneously working to obtain regulatory approvals for ex-US markets from our India plant. Our consumer business delivered healthy mid-teen growth, seamlessly collaborating with various stakeholders for smooth transition to new GST rates changes.” The company’s CDMO business for the quarter under review stood at ₹1,044 crore, down 21 per cent. Its Complex Hospital Generics (CHG) segment was flat at ₹644 crore and the consumer healthcare segment grew by 15 per cent at ₹319 crore. On the consumer healthcare outlook, Piramal told businessline, the company’s power brands grew close to 20 per cent and the GST transition was managed “pretty well with no loss of sales.” As more drugmakers carve out their healthcare businesses, could Piramal Pharma be looking at acquisitions to strengthen its business? “In this excitement of consumer products, everyone’s valuations are very high,” she said, adding that their view is to scale-up their own brands including Little’s, Lacto, and the i-range, for example. Published on November 6, 2025
